ClinicalTrials.gg
CompletedNCT01794741Updated Mar 31, 2015Results posted

3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis

A Phase 3 interventional study of Dymista Nasal Spray and Fluticasone propionate nasal spray in Allergic Rhinitis, sponsored by Meda Pharmaceuticals. Completed at 41 sites in United States. Open to participants aged 4 Years to 11 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-03-31.

Sponsored by Meda Pharmaceuticals (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
405
Allocation
Randomized
Ages
4 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies testing fluticasone in Rhinitis, Allergic — none open to participants now, 1 under way, none of them phase 3. Fluticasone · Rhinitis, Allergic.

Enrollment
8th of 34
405 · median 63
Started
2013
with 1 other
Phase 3
9 of 34
none open now
Registered
26th of 34
by date
Lead sponsor
1 of 34
Meda Pharmaceuticals

Among the 34 studies testing fluticasone in Rhinitis, Allergic, this one is the 8th largest by enrollment, is one of 2 that started in 2013, is one of 9 in phase 3, and was the 26th registered.

Rhinitis, Allergic

717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.

Browse Rhinitis, Allergic studies →

Open to participants now

None of the 34 studies testing fluticasone in Rhinitis, Allergic is open now. The open studies under Rhinitis, Allergic, anywhere →

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.

This study: 4 Years to 11 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 34 studies testing fluticasone in Rhinitis, Allergic as a file.
02

Study summary

This is a 3 month safety study of Dymista Nasal spray in children aged 4 to 11 years with allergic rhinitis

03

Conditions studied

  • Allergic Rhinitis

Browse trials for

04

Who can participate

Ages eligible
4 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects ≥ 4 years to \<12 years, inclusive at the screening visit
  • A history of allergic rhinitis (AR)
  • The parent/caregiver must provide written and the child must provide assent
  • Willing and able to comply with the study requirements
  • Require treatment with Dymista Nasal Spray, based on the Investigator's assessment (based on medical history, physical examination, etc.) of the subjects' clinical condition, at both the Screening and Randomization Visits
  • General good health and free of any disease or concomitant treatment that could interfere with the interpretation of the study results as determined by the investigator or the sponsor's medical officer
  • Subjects receiving immunotherapy injections (antigen desensitization) must be on a stable maintenance regimen for at least 30 days before the first study visit (adjustments to regimen following a brief period of missed injections do not preclude participation)

Exclusion criteria

Exclusion Criteria:

  • On nasal examination, subjects with superficial nasal mucosal erosion, moderate nasal mucosal erosion, nasal mucosal ulceration, nasal septum perforation
  • Nasal disease(s) likely to affect deposition of intranasal medication, such as acute or chronic sinusitis, rhinitis medicamentosa, polyposis or clinically significant nasal structural abnormalities
  • Nasal surgery or sinus surgery within the previous year
  • The use of any drug within 30 days prior to Visit 1. No investigational products are permitted for use during the conduct of this study
  • Presence of any to azelastine hydrochloride and/or fluticasone propionate or drugs similar to azelastine hydrochloride and/or fluticasone propionate
  • Respiratory tract infections within two weeks prior to Visit 1.
  • Subjects with significant pulmonary disease including asthma. Subjects with intermittent asthma who only require short-acting inhaled bronchodilators (not more often than twice per week) and who do not have nocturnal awakening as a result of asthma are eligible for enrollment
  • Chronic obstructive sleep apnea syndrome (clinical diagnosis)
  • Existence of any surgical or medical condition, which in the opinion of the investigator or sponsor's medical monitor, might significantly alter the absorption, distribution, metabolism, or excretion of study drug or that might significantly affect the subject's ability to complete this trial
  • Clinically relevant abnormal physical findings or laboratory results which, in the opinion of the investigator, would interfere with the objectives of the study or that may preclude compliance with the study procedures
  • Family members of research center or private practice personnel who are directly involved in this study are excluded
  • Members of the same family cannot enroll in the study at the same time.
  • Subjects who have used medications or therapies that could interfere with safety evaluations (see Sections 4.0 and 5.0) and have not had the proper washouts from these medications or therapies
  • Any behavioral condition which could affect subject's ability to accurately report symptoms to the caregiver such as developmental delay, attention deficit disorder, and autism
  • Positive pregnancy test in female subjects ≥ 9 years of age
  • Females who are pregnant or nursing practicing a medically acceptable method of
  • Subjects who fail to complete the symptom diary during the lead-in period, defined as missing data for >50% of entries
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
405 participants (actual)

Study arms

  • Active comparator
    Dymista nasal spray

    azelastine 137mcg per spray/fluticasone propionate 50mcg per spray one spray per nostril twice a day for three months

    Drug: Dymista Nasal Spray

  • Active comparator
    fluticasone propionate nasal spray

    fluticasone propionate nasal spray 50mcg per spray per nostril twice a day

    Drug: Fluticasone propionate nasal spray

06

What researchers measure

Primary outcomes

  1. Adverse Events Report

    reports of treatment emergent adverse events

    Time frame: 3 months of treatment

07

Results

Posted Mar 31, 2015

Participant flow

Participant flow — Overall Study
MilestoneDymista Nasal SprayFluticasone Propionate Nasal Spray
Started304101
Completed28592
Not completed199

Outcome measures

PrimaryAdverse Events Report

reports of treatment emergent adverse events

Time frame:
3 months of treatment
Reported as:
Number · event
Adverse Events Report
eventDymista Nasal SprayFluticasone Nasal Spray
Adverse Events Report12437

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dymista Nasal Spray—1/304 (0.3%)114/304 (37.5%)
Fluticasone Propionate Nasal Spray—0/101 (0%)25/101 (24.8%)
Most frequent serious events
Most frequent serious events
EventDymista Nasal SprayFluticasone Propionate Nasal Spray
gastroenteritis elevated LFTGastrointestinal disorders1/3040/101
Most frequent other events
Most frequent other events
EventDymista Nasal SprayFluticasone Propionate Nasal Spray
epistaxisRespiratory, thoracic and mediastinal disorders30/3049/101
headacheGeneral disorders20/3043/101
coughRespiratory, thoracic and mediastinal disorders11/3043/101
pyrexiaGeneral disorders10/3042/101
otitis mediaEar and labyrinth disorders9/3043/101
oropharyngeal painRespiratory, thoracic and mediastinal disorders9/3040/101
vomitingGastrointestinal disorders9/3042/101
abdominal pain upperGastrointestinal disorders8/3042/101
upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders8/3041/101

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Dymista Nasal SprayFluticasone Propionate Nasal SprayTotal
<=18 years304101405
Between 18 and 65 years000
>=65 years000
Age, Continuous
Age, Continuous(years)Dymista Nasal SprayFluticasone Propionate Nasal SprayTotal
Mean8.1 ± 2.078.1 ± 1.948.1 ± 1.9
Sex: Female, Male
Sex: Female, Male(Participants)Dymista Nasal SprayFluticasone Propionate Nasal SprayTotal
Female12149170
Male18352235
Region of Enrollment
Region of Enrollment(participants)Dymista Nasal SprayFluticasone Propionate Nasal SprayTotal
United States304101405
08

Study locations

41 sites
  • Clinical Research Center of Alabama,LLC
    Birmingham, Alabama 35209, United States
  • Little Rock Allergy and Asthma Clinical research Center
    Little Rock, Alaska 72205, United States
  • West Coast Clinical Trials
    Costa Mesa, California 92626, United States
  • Allergy & Asthma Care Center of So. Cal
    Long Beach, California 90808, United States
  • Southern California Research
    Mission Viejo, California 92691, United States
  • Allergy Associates Medical Group Inc
    San Diego, California 92120, United States
  • Allergy & Asthma Associates of Santa Clara Valley Research Cntr
    San Jose, California 95117, United States
  • Storms Clinical Research Institute
    Colorado Springs, Colorado 80907, United States
  • Colorado Allergy and Asthma Centers, PC
    Denver, Colorado 80230, United States
  • Asthma and Allergy Associates, PC
    Pueblo, Colorado 81001, United States
  • Allergy and Asthma Care of Florida
    Ocala, Florida 34471, United States
  • Atlanta Allergy and Asthma Clinic
    Stockbridge, Georgia 30281, United States
  • Idaho Allergy
    Eagle, Idaho 83616, United States
  • Sneeze, Wheeze and Itch Associates
    Normal, Illinois 61761, United States
  • Clinical Research Institute of Indiana
    Indianapolis, Indiana 46208, United States
  • Family Allergy and Asthma Reserach
    Louisville, Kentucky 40215, United States
  • Respiratory Medicine Research Institute of Michigan
    Ypsilanti, Michigan 48197, United States
  • Clinical Reseacrh Institute
    Minneapolis, Minnesota 55402, United States
  • The Clinical Research Center
    St. Louis, Missouri 63141, United States
  • Clinical Research of the Ozarks,Inc
    Warrensburg, Missouri 64093, United States
  • Midwest Allergy and Asthma Clinic
    Omaha, Nebraska 68130, United States
  • The Asthma and Allergy Center, PC
    Papillion, Nebraska 68046, United States
  • Atlantic Research Center
    Ocean, New Jersey 07712, United States
  • Asthma, Sinus & Allergy Centers, LLC
    Warren, New Jersey 07059, United States
  • North Carolina Clinical Research
    Raleigh, North Carolina 27607, United States
  • Bernstein Clinical Research Center
    Cincinnati, Ohio 45231, United States
  • Allergy, Asthma & Clinical Research Center
    Oklahoma City, Oklahoma 73120, United States
  • Oklahoma Institute of Allergy and Asthma
    Oklahoma City, Oklahoma 73131, United States
  • Baker Allergy Asthma & Dermatology Ctr LLC
    Lake Oswego, Oregon 97035, United States
  • Allergy and Asthma Specialist PC
    Blue Bell, Pennsylvania 19422, United States
  • National Allergy, Asthna & Urticaria Centers of Charleston Pa
    Charleston, Pennsylvania 29406, United States
  • Allergy and Clinical Immunology Associates
    Pittsburgh, Pennsylvania 15241, United States
  • Asthma and Allergy Research Associate
    Upland, Pennsylvania 19013, United States
  • ADAC Research, PA
    Greenville, South Carolina 29607, United States
  • AARA Research Center
    Dallas, Texas 75231, United States
  • Texas Allergy Research Center
    Dallas, Texas 75246, United States
  • Central Texas Health Research
    New Braunfels, Texas 78130, United States
  • Paul H Ratner,MD
    San Antonio, Texas 78229, United States
  • Live Oak Allergy and Asthma Clinic
    San Antonio, Texas 78233, United States
  • Allergy Asthma Research Institute
    Waco, Texas 76712, United States
  • Pediatric Allergy,Asthma and Immunology/Allergy& Asthma care of Waco
    Waco, Texas 76712, United States
09

References and documents

Publications

  • Berger W, Sher E, Gawchik S, Fineman S. Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: A randomized clinical trial. Allergy Asthma Proc. 2018 Mar 1;39(2):110-116. doi: 10.2500/aap.2018.39.4116. PubMed 29490769 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2013 and a primary completion of Nov 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2013
First posted
Feb 20, 2013
Start
Feb 2013
Primary completionActual
Nov 2013
Results first posted
Mar 31, 2015
Last update
Mar 31, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01794741
Responsible party
Sponsor
First posted
Feb 20, 2013
Start date
Feb 2013
Primary completion
Nov 2013
Results posted
Mar 31, 2015
Last update
Mar 31, 2015

Study contacts

Nancy Ruiz, M.D.
study director · Sponsor GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray · Fluticasone

Start the discussion